Why the study?
Does the R(-)-enantiomer of tocainide have a better margin of safety and antiarrhythmic efficacy compared to the S(+)-enantiomer and racemic mixture in preclinical models?
Does the R(-)-enantiomer of tocainide have a better margin of safety and antiarrhythmic efficacy compared to the S(+)-enantiomer and racemic mixture in preclinical models?
The R(-)-enantiomer of tocainide demonstrates a superior margin of safety and greater antiarrhythmic potency compared to the S(+)-enantiomer and racemic mixture in preclinical models.
No takes yet. Share an insight, caveat, or question.
R-T merits enantiomer-specific testing in arrhythmia models; leaves open clinical translation of its safety margin.
Block et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: